NM-AIST Repository

https://dspace.mm-aist.ac.tz

Life sciences and Bio-engineering

Research Articles [LISBE]

2022-08-04

# Impact of early diagnosis of impaired glucose regulation in tuberculosis: Comparison of clinical outcomes in people with tuberculosis in Tanzania

Byashalira, Kenneth

John Wiley & Sons, Inc.

https://doi.org/10.1111/tmi.13806

Provided with love from The Nelson Mandela African Institution of Science and Technology

Impact of early diagnosis of impaired glucose regulation in tuberculosis: Comparison of clinical outcomes in people with tuberculosis in Tanzania

Kenneth Byashalira, Nyasatu Chamba, Yosra Alkabab, Peter Mbelele, Emmanuel Mpolya, Nyanda Ntinginya, PendoMartha J. Shayo, Kaushik L. Ramaiya, Troels Lillebaek, Scott K. Heysell, Blandina T. Mmbaga, Ib C. Bygbjerg, Stellah Mpagama, Dirk L. Christensen,

To download the complete text, click that link.

DOI: https://doi.org/10.1111/tmi.13806

### Abstract

## Objective

Diabetes mellitus (DM) has been known to compromise tuberculosis (TB) treatment outcomes. Association data are limited for early hyperglycaemia detection and TB treatment outcomes. Thus, we assessed treatment outcomes including time to sputum conversion and death in TB participants with or without hyperglycaemia.

### Methods

A prospective cohort study recruited TB participants receiving anti-TB treatment at health facilities in Tanzania between October 2019 and September 2020. Hyperglycaemia was defined as having pre-existing DM or pre-treatment random blood glucose of ≥7.8mmol/L, in combination categorised as impaired glucose regulation (IGR). Those with IGR were further screened for hyperglycaemia severity using glycated haemoglobin. In case of unknown status, participants were tested for HIV. Time to death was determined at 6 months of TB treatment.

### Results

Of 1,344 participants, 187 (13.9%) had IGR, of whom 44 (23.5%) were HIV co-infected. Overall treatment success was 1,206 (89.7%), and was similar among participants with or without IGR (p>0.05). Time to death for participants with and without IGR was 18 versus 28 days (p=0.870), respectively. Age  $\geq$ 40 years (p=0.038), bacteriological positive (p=0.039), HIV (p=0.009), or recurrent TB (p=0.017) predicted death or treatment success during TB treatment in adjusted multivariable models.

# Conclusion

IGR did not influence clinical outcomes in TB patients with or without IGR in a programme of early IGR diagnosis and integration TB, HIV and DM care. Early detection and co-management of multi-morbidities among people diagnosed with TB may reduce likelihood of poor treatment outcomes in a programmatic setting.